Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.56 |
| ▸ | CES1 | P23141 | 4/20 | 0.56 |
| ▸ | BCHE | P06276 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | ALB | P02768 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 2/20 | 0.36 |
| ▸ | F10 | P00742 | 2/20 | 0.36 |
| ▸ | F12 | P00748 | 1/20 | 0.36 |
| ▸ | F7 | P08709 | 1/20 | 0.36 |
| ▸ | F3 | P13726 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | KLK1 | P06870 | 1/20 | 0.34 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3647753 | 0.98 | CES2 (0.54) | CES2CES1BCHEHPGDCTSL | |
| Hydrochloric Acid SCHEMBL10434081 | 0.96 | CES2 (0.52) | CES2CES1BCHEHPGDCTSL | |
| SCHEMBL29970881 | 0.81 | CES2 (0.52) | CES2CES1BCHEHPGDCTSL | |
| SCHEMBL522903 | 0.81 | CES2 (0.52) | CES2CES1BCHEHPGDCTSL | |
| SCHEMBL20599650 | 0.79 | CES2 (0.54) | CES2CES1BCHEF2F10 | |
| SCHEMBL16935755 | 0.79 | CES2 (0.58) | CES2CES1BCHEHPGDCTSL | |
| Hydrochloric Acid SCHEMBL319729 | 0.79 | CES2 (0.50) | CES2CES1BCHEHPGDCTSL | |
| SCHEMBL4223326 | 0.78 | BACE1 (0.42) | CES2CES1BCHEALBBACE1 | |
| Hydrochloric Acid SCHEMBL21553857 | 0.78 | ALB (0.53) | CES2CES1BCHEALBBACE1 | |
| SCHEMBL27971210 | 0.78 | BACE1 (0.42) | CES2CES1BACE1KAT6AF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3732183-A1 | METAL COMPLEX COMPRISING AMIDINE AND THIOPHENE FUSED CYCLOPENTADIENYL LIGANDS | Arlanxeo Netherlands B.V. (NL) | 2020-11-04 | — | — | EP | disclosed |
| CN-107922529-A | Catalyst system | 阿朗新科荷兰有限公司 | 2018-04-17 | — | — | CN | disclosed |
| CN-107207532-A | Nitroimidazole derivatives against tuberculosis | 南京明德新药研发股份有限公司 | 2017-09-26 | — | — | CN | disclosed |
| WO-2011079118-A1 | PTERIDINONES AS INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC (US) | 2011-06-30 | — | — | WO | disclosed |
| US-7645776-B2 | (R)-1-{2-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone; carnitine-dependent palmitoyltransferases (CPTs); reduce liver beta -oxidation, consequently inhibit gluconeogenesis and therefore counteract hyperglycemia | HOFFMANN-LA ROCHE INC. (US) | 2010-01-12 | — | — | US | disclosed |
| CN-101622284-A | Elastomeric compound | DSM IP ASSETS BV | 2010-01-06 | — | — | CN | disclosed |
| EP-1924611-A1 | PROCESS FOR THE PREPARATION OF A METAL-ORGANIC COMPOUND COMPRISING A SPECTATOR LIGAND | DSMIP Assets B.V. (NL) | 2008-05-28 | — | — | EP | disclosed |
| US-20070129544-A1 | (R)-1-{2-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone; carnitine-dependent palmitoyltransferases (CPTs); reduce liver beta -oxidation, consequently inhibit gluconeogenesis and therefore counteract hyperglycemia | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | US | disclosed |
| WO-2007031295-A1 | PROCESS FOR THE PREPARATION OF A METAL-ORGANIC COMPOUND COMPRISING A SPECTATOR LIGAND | DSM IP ASSETS B.V. (NL) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129544-A1 | (R)-1-{2-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone; carnitine-dependent palmitoyltransferases (CPTs); reduce liver beta -oxidation, consequently inhibit gluconeogenesis and therefore counteract hyperglycemia | CPT1A, CPT1B, CPT2 | CES2 38/4885CES1 5/4885BCHE 1185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.